Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preclinical efficacy of MEK inhibition in Nras-mutant AML.

Blood - 18 Dec 2014

Burgess Michael R, Hwang Eugene, Firestone Ari J, Huang Tannie, Xu Jin, Zuber Johannes, Bohin Natacha, Wen Tiffany, Kogan Scott C, Haigis Kevin M, Sampath Deepak, Lowe Scott, Shannon Kevin, Li Qing

Abstract excerpt

Oncogenic NRAS mutations are highly prevalent in acute myeloid leukemia (AML). Genetic analysis supports the hypothesis that NRAS mutations cooperate with antecedent molecular lesions in leukemogenesis, but have limited independent prognostic significance. Using short hairpin RNA-mediated knockdown in human cell lines and primary mouse leukemias, we show that AML cells with NRAS/Nras mutations are dependent on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genes, ras
Share to Hematopoietic Stem Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Kinase Kinases

Share to MAP Kinase Signaling System

Share to Monomeric GTP-Binding Proteins

Share to RNA, Small Interfering

Share to Stem Cells

Share to Transgenes

Source

Open in PubMed Open full text

Identifiers

PMID: 25361812
DOI: 10.1182/blood-2014-05-574582
PMCID: PMC4271180

Genes

NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical efficacy of MEK inhibition in Nras-mutant AML.PMID 25361812Read ↗

Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.Semantic proximity Read ↗

Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice.Semantic proximity Read ↗

MEK1 is required for the development of NRAS-driven leukemia.Semantic proximity Read ↗

Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions.Semantic proximity Read ↗

Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice.Semantic proximity Read ↗

Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.Semantic proximity Read ↗

Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia.Semantic proximity Read ↗

Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity.Semantic proximity Read ↗

Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.Semantic proximity Read ↗

RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemiaSemantic proximity Read ↗

Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.Semantic proximity Read ↗

NRAS G12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.